Prochlorperazine 12.5mg/1mL Injection

Prochlorperazine 12.5mg/1mL is an injectable phenothiazine antiemetic and vestibular suppressant used under medical supervision for nausea, vomiting, and vertigo for prochlorperazine treatment. In some settings it is also used for acute severe agitation or psychotic symptoms, but indication and dosing differ. Prochlorperazine blocks dopamine receptors in the brain's vomiting center and vestibular pathways, helping reduce nausea and dizziness related to inner-ear disorders such as Meniere's disease. Because it can cause sedation, low blood pressure, extrapyramidal reactions, dystonia, akathisia, parkinsonism, and rarely neuroleptic malignant syndrome, injection should be given with observation. Important risks include QT prolongation or arrhythmia, severe drowsiness, anticholinergic effects, jaundice, blood-count problems, and injection-site reactions.
Prochlorperazine 12.5mg/1mL is given by a healthcare professional by the prescribed route. The patient should be monitored for drowsiness, low blood pressure, abnormal movements, and symptom response.
Prochlorperazine blocks dopamine receptors involved in vomiting and vestibular signaling, reducing nausea, vomiting, and vertigo symptoms.
Possible effects include drowsiness, dizziness, dry mouth, constipation, low blood pressure, blurred vision, and injection-site reactions. Serious concerns include dystonia, severe restlessness, parkinsonism, QT prolongation, arrhythmia, neuroleptic malignant syndrome, jaundice, and severe allergy.
Review Parkinson's disease, dementia, glaucoma, prostate enlargement, seizures, liver disease, heart rhythm disease, low potassium/magnesium, pregnancy, breastfeeding, alcohol, sedatives, anticholinergics, and QT-prolonging medicines.
Nausea, vomiting, vertigo, or selected specialist indications when injectable prochlorperazine is prescribed.
Can provide supervised relief from significant nausea, vomiting, or vestibular dizziness when oral therapy cannot be used or rapid control is needed.
Prochlorperazine 12.5mg/1mL is used for nausea, vomiting, and vertigo for injectable prochlorperazine treatment.
Yes. Drowsiness and dizziness can occur, so driving or machinery should be avoided until effects are known.
Neck spasm, eye-rolling, restlessness, tremor, stiffness, or abnormal movements should be reported quickly.
Prochlorperazine can be relevant to QT prolongation and arrhythmia risk, especially with interacting medicines or electrolyte problems.
No. Injectable prochlorperazine should be administered by healthcare professionals.
Prochlorperazine, Antiemetic medicine, Vertigo nausea vomiting, Phenothiazine dopamine blocker, Extrapyramidal symptoms, QT prolongation risk, AR: Prochlorperazine / حقن, FR: Prochlorperazine /, PT: Prochlorperazine / injeção, ES: Prochlorperazine / inyección, RU: Prochlorperazine / инъекция, ID: Prochlorperazine / injeksi, VI: Prochlorperazine / thuốc tiêm, MS: Prochlorperazine / suntikan, TL: Prochlorperazine / iniksyon, ZH-SG: Prochlorperazine / 注射剂
International B2B Enquiry
Send a structured B2B enquiry for Prochlorperazine 12.5mg/1mL Injection under Digestive Care. Global Medicines Export helps international buyers review product information, pack details, quantity requirements, destination-market needs, quotation support and export documentation coordination from India.
Product name, required strength or pack, expected quantity, destination country, buyer type and preferred manufacturer if any.
Availability, quotation support, documentation expectations and shipment-ready order communication can be reviewed before confirmation.
Commercial invoice, packing information, manufacturer details, batch details and supporting documents where applicable and available.
Product availability, quotation, and documentation support are coordinated for international B2B enquiries.
Prochlorperazine 12.5mg/1mL Injection